Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03701282
Title Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

chronic lymphocytic leukemia

Therapies

Ibrutinib + Obinutuzumab

Ibrutinib + Obinutuzumab + Venetoclax

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.